<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/12/09/zacks-cns-pharmaceuticals-inc-nasdaqcnsp-receives-average-rating-of-strong-buy-from-brokerages.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-12-09T16:46:46+00:00"/>
    <meta property="og:title" content="Zacks: CNS Pharmaceuticals Inc (NASDAQ:CNSP) Receives Average Rating of “Strong Buy” from Brokerages"/>
    <meta property="og:description" content="Shares of CNS Pharmaceuticals Inc (NASDAQ:CNSP) have been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating. Zacks has also assigned CNS Pharmaceuticals an industry rank of […]"/>
  </head>
  <body>
    <article>
      <h1>Zacks: CNS Pharmaceuticals Inc (NASDAQ:CNSP) Receives Average Rating of “Strong Buy” from Brokerages</h1>
      <address><time datetime="2019-12-09T16:46:46+00:00">09 Dec 2019, 16:46</time> by <a rel="author" href="https://www.thecerbatgem.com/author/jessica" target="_blank">Jessica Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/generic-stocks.jpg"/>
      </figure>
      <p>Shares of CNS Pharmaceuticals Inc (NASDAQ:CNSP) have been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> reports. One equities research analyst has rated the stock with a strong buy rating.</p>
      <p>Zacks has also assigned CNS Pharmaceuticals an industry rank of 58 out of 255 based on the ratings given to its competitors.</p>
      <p>Separately, Benchmark assumed coverage on CNS Pharmaceuticals in a research note on Wednesday, December 4th. They issued a “speculative buy” rating for the company.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/CNSP/price-target/">CNSP stock</a> traded down $0.02 during mid-day trading on Friday, reaching $3.97. The company had a trading volume of 1,341 shares, compared to its average volume of 123,930. CNS Pharmaceuticals has a 52 week low of $3.86 and a 52 week high of $5.69.</p>
      <p>
        <b>CNS Pharmaceuticals Company Profile</b>
      </p>
      <p>CNS Pharmaceuticals, Inc, a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. Its lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma.</p>
      <p>Recommended Story: <a href="https://www.marketbeat.com/insider-trades/">Insider Trading</a></p>
      <p>
        <a href="https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&amp;ADID=AMERBMN_CONTENT_ZER&amp;skip_rpt_name_check=skip_rpt_name_check&amp;t=CNSP">Get a free copy of the Zacks research report on CNS Pharmaceuticals (CNSP)</a>
      </p>
      <p>For more information about research offerings from Zacks Investment Research, visit <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks.com</a></p>
    </article>
  </body>
</html>